Clinical trial
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
NCT00781911 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2009
- Completion date
- May 31, 2016
- Enrollment
- 43 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.